SD Dojavi
OSMRTNICE
PRETPLATA
PREMIUM
stdClass Object ( [id] => 1131624 [title] => Jesmo li došli do prekretnice u borbi protiv covida? Prvi rezultati testiranja Merckova lijeka obećavaju, evo o kakvim se tabletama radi [alias] => jesmo-li-dosli-do-prekretnice-u-borbi-protiv-covida-prvi-rezultati-testiranja-merckova-lijeka-obecavaju-evo-o-kakvim-se-tabletama-radi [catid] => 241 [published] => 1 [introtext] => [fulltext] =>

Dok su u početku pandemije farmaceutske kompanije uglavnom bile fokusirane na razvoj cjepiva, sada mnoge od njih pokušavaju razviti specifične lijekove protiv covida-19. Tako je multinacionalni farmaceutski div Merck & Co. u suradnji s biotehnološkom kompanijom Ridgeback Biotherapeutics razvio antivirusni lijek molnupiravir koji je već prošao prvu fazu kliničkih ispitivanja, piše Jutarnji list.

- Riječ je o lijeku koji je po svom djelovanju sličan remdesiviru koji se već koristi u liječenju covida-19, i koji blokira replikaciju virusnog genoma. Molnupiravir je, također, analog nukleotida, a virusnu replikaciju ometa tako da se ubacuje u lanac virusne mRNA kad se virus razmnaža čime nastaju nepotpuni lanci koji se ne mogu dalje razmnažati. Međutim, remdesivir se mora davati intravenski i stoga nije praktično davati ga osobama koje ne leže u bolnici. Stoga se remdesivir koristi kad je bolest već uznapredovala i tada nije naročito efikasan – pojasnio je virusni imunolog dr. Luka Čičin-Šain, voditelj Odjela za virusnu imunologiju u Helmholtz centru za infektivna istraživanja u Braunschweigu.

- Za razliku od remdesivira, molnupiravir se prima kao tableta i može ga se početi davati i u ranijim fazama bolesti, što je korisno jer se time sprječava da se virus proširi po plućima, što budi nadu da bi njegov učinak mogao biti bolji. Molnupiravir se nalazi u kombiniranoj drugoj i trećoj fazi kliničkog istraživanja što znači da još nije odobren za upotrebu – dodao je Čičin-Šain.

Molnupiravir je antivirusni lijek širokog spektra što znači da može djelovati protiv velikog broja virusa. Njegov razvoj započeo je još 2013. godine na američkom Sveučilištu Emory, odnosno sveučilišnoj spin-off kompaniji Drug Innovation Ventures at Emory (DRIVE) koju je zatim kupio Ridgeback Biotherapeutics iz Miamija. Prvobitna ideja je bila testirati molnupiravir u kliničkim pokusima kao potencijalni lijek protiv gripe, no kada je buknula pandemija koronavirusa, plan je izmijenjen. Kako se prošlog proljeća molnupiravir pokazao učinkovit u liječenju laboratorijskih miševa zaraženih koronavirusom, kompanija Ridgeback Biotherapeutics se, u suradnji s farmaceutskim divom Merck&Co., preusmjerila na razvoj lijeka protiv covida-19.

---

image
Luka Čičin-Šain
Julian Stratenschulte/AFP
---

Izvršni direktor Mercka Robert Davis nedavno je izjavio da se idućih tjedana očekuju preliminarni rezultati druge i treće faze kliničkih ispitivanja u koju je uključeno 1850 ispitanika. Budu li ti klinički pokusi uspješni, kompanija bi već krajem godine od američke Agencije za hranu i lijekove (FDA) zatražila dozvolu za hitnu uporabu. Lijek bi se uzimao pet do 10 dana nakon pojave simptoma covida-19 i to dva puta dnevno.

Uz molnupiravir, obećavajuće rezultate u kliničkim pokusima pokazuju još dva antivirusna lijeka: Pfizerov PF-07321332 i AT-527, koji su razvili Roche i Atea Pharmaceuticals. Oba lijeka, koji su također tablete, djeluju tako da blokiraju enzime SARS-Cov-2 neophodne za umnažanje virusa i širenje zaraze. Pfizer je 1. rujna pokrenuo kombinirano ispitivanje faze 2 i 3 svog lijeka, a dužnosnici kompanije Atea Pharmaceuticals rekli su da očekuju rezultate ispitivanja u fazi 2 i fazi 3 krajem ove godine.

- Oralni antivirusni lijekovi imaju potencijal ne samo skratiti trajanje covida-19, već imaju i potencijal ograničiti prijenos na ljude u vašem kućanstvu ako ste bolesni - rekao je za CNN Timothy Sheahan, virolog sa Sveučilišta Sjeverna Karolina.

Luka Čičin-Šain upozorava kako je glavni problem kod akutnih respiratornih infekcija, bilo da je riječ o covidu ili gripi, da se zaraza kod pacijenta razvija jako brzo.

- Mislim da razmišljanja idu u smjeru individulazirane terapije kako bi se lijekovi profilaktički davali starijima od 70 godina, pretilima, osobama koje pate od dijabetesa i kardiovaskularnih bolesti itd. čim im se dijagnosticira covid, a ne kada su već u jedinici intenzivnog liječenja. No, takvi lijekovi trebaju biti jednostavni u primjeni van bolnica ili ordinacija. Idealan bi bio lijek koga se može koristiti kao tabletu, slično antibioticima. Ova studija budi nadu da bi takav lijek, koji bi bio učinkovit kod koronavirusa, uskoro mogao dokazati svoju efikasnost i u kliničkim uvjetima – rekao je Čičin-Šain.

[video] => [gallery] => [extra_fields] => Array ( [1] => stdClass Object ( [id] => 2 [name] => Superscript Title [value] => prošao prvu fazu [type] => textarea [group] => 9 [published] => 1 [ordering] => 2 [alias] => SuperscriptTitle ) [2] => stdClass Object ( [id] => 61 [name] => Contains Infographic [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 4 [alias] => contains_infographic ) [3] => stdClass Object ( [id] => 62 [name] => Without ads [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 5 [alias] => Withoutads ) [4] => stdClass Object ( [id] => 63 [name] => Photo gallery [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 6 [alias] => Photo_gallery ) [5] => stdClass Object ( [id] => 64 [name] => Promo [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 7 [alias] => promo ) [7] => stdClass Object ( [id] => 67 [name] => Contains video [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 9 [alias] => contains_video ) [8] => stdClass Object ( [id] => 68 [name] => Premium content [value] => ON [type] => radio [group] => 9 [published] => 1 [ordering] => 10 [alias] => premium_content ) [9] => stdClass Object ( [id] => 69 [name] => Exclude comments [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 11 [alias] => exclude_comments ) [10] => stdClass Object ( [id] => 70 [name] => Open link in new window [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 12 [alias] => open_link_in_new_window ) [11] => stdClass Object ( [id] => 71 [name] => Horizontal crop of the main photo [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 13 [alias] => horizontal_crop_of_the_main_photo ) [12] => stdClass Object ( [id] => 73 [name] => No-index [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 15 [alias] => no_index ) [13] => stdClass Object ( [id] => 74 [name] => No-cache [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 16 [alias] => no_cache ) [14] => stdClass Object ( [id] => 77 [name] => Don't show on the front page [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 17 [alias] => dont_show_on_the_front_page ) [15] => stdClass Object ( [id] => 78 [name] => Related on bottom [value] => ON [type] => radio [group] => 9 [published] => 1 [ordering] => 18 [alias] => related_on_bottom ) [16] => stdClass Object ( [id] => 79 [name] => Live button [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 19 [alias] => live_button ) [25] => stdClass Object ( [id] => 87 [name] => Instant articles [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 28 [alias] => instant_articles ) [26] => stdClass Object ( [id] => 91 [name] => S preporučuje [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 29 [alias] => s_preporucuje ) [27] => stdClass Object ( [id] => 92 [name] => S voli [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 30 [alias] => s_voli ) [28] => stdClass Object ( [id] => 93 [name] => Layout with three photos [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 31 [alias] => layout_with_three_photos ) [29] => stdClass Object ( [id] => 94 [name] => Gallery in the article [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 32 [alias] => gallery_in_the_article ) [30] => stdClass Object ( [id] => 95 [name] => Required views [value] => 0 [type] => textfield [group] => 9 [published] => 1 [ordering] => 33 [alias] => required_views ) [31] => stdClass Object ( [id] => 96 [name] => FullHD image [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 34 [alias] => fullhd_image ) [32] => stdClass Object ( [id] => 98 [name] => Paid Article [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 36 [alias] => paid_article ) ) [extra_fields_search] => prošao prvu fazu 1 1 1 1 1 1 0 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 [created] => 2021-10-01 14:59:37 [created_by] => 264 [created_by_alias] => Tanja Rudež/JL [checked_out] => 0 [checked_out_time] => 0000-00-00 00:00:00 [modified] => 2021-10-01 15:08:44 [modified_by] => 0 [publish_up] => 2021-10-01 15:07:00 [publish_down] => 0000-00-00 00:00:00 [trash] => 0 [access] => 1 [ordering] => 0 [featured] => 0 [featured_ordering] => 0 [image_caption] => [image_credits] => [video_caption] => [video_credits] => [hits] => 488 [params] => Joomla\Registry\Registry Object ( [data:protected] => stdClass Object ( [enable_css] => 1 [jQueryHandling] => 1.8remote [backendJQueryHandling] => remote [userName] => 1 [userImage] => 1 [userDescription] => 1 [userURL] => 1 [userEmail] => 0 [userFeedLink] => 1 [userFeedIcon] => 1 [userItemCount] => 30 [userItemTitle] => 1 [userItemTitleLinked] => 1 [userItemDateCreated] => 1 [userItemImage] => 1 [userItemIntroText] => 1 [userItemCategory] => 1 [userItemTags] => 1 [userItemCommentsAnchor] => 1 [userItemReadMore] => 1 [userItemOCMPlugins] => 1 [authorsListLimit] => 61 [tagItemCount] => 61 [tagItemTitle] => 1 [tagItemTitleLinked] => 1 [tagItemDateCreated] => 1 [tagItemImage] => 1 [tagItemIntroText] => 1 [tagItemCategory] => 1 [tagItemReadMore] => 1 [tagItemExtraFields] => 1 [tagOrdering] => [tagFeedLink] => 1 [tagFeedIcon] => 1 [genericItemCount] => 61 [genericItemTitle] => 1 [genericItemTitleLinked] => 1 [genericItemDateCreated] => 1 [genericItemImage] => 1 [genericItemIntroText] => 1 [genericItemCategory] => 1 [genericItemReadMore] => 1 [genericItemExtraFields] => 1 [genericFeedLink] => 1 [genericFeedIcon] => 1 [instantArticlesLimit] => 100 [instantArticlesExtraField] => 87 [instantArticlesExtraFieldON] => 2 [instantArticlesCategoriesChildren] => 0 [instantArticlesTitle] => [instantArticlesDescription] => [mainTagCategories] => Array ( [0] => 119 [1] => 396 [2] => 383 [3] => 424 [4] => 250 [5] => 251 [6] => 452 [7] => 252 [8] => 477 [9] => 253 [10] => 254 [11] => 255 [12] => 483 [13] => 256 [14] => 300 [15] => 257 [16] => 258 [17] => 260 ) [relatedItemsCategoriesChildren] => 1 [mobileJsonCustomHomepage] => 0 [mobileJsonQuoteModule] => 0 [mobileJsonWeatherModule] => 0 [mobileJsonLimit] => [mobileJsonObituary] => 0 [mobileApi2Enabled] => 1 [mobileApi2UserAgent] => OCM Mobile Articles [mobileApi2ImagePrefix] => h [mobileApi2ImageSuffix] => 1280 [mobileApi2DefaultAuthorImage] => /images/jpgs/user_face.jpg [mobileApi2TagLimit] => 50 [mobileApi2TagOrdering] => publishUp [mobileApi2TagCategories] => stdClass Object ( [mobileApi2TagCategories0] => stdClass Object ( [mobileApi2TagCategoriesMenuitem] => 101 [mobileApi2TagExcludeCategories] => Array ( [0] => 318 [1] => 323 [2] => 301 [3] => 406 [4] => 417 ) ) [mobileApi2TagCategories1] => stdClass Object ( [mobileApi2TagCategoriesMenuitem] => 328 ) [mobileApi2TagCategories2] => stdClass Object ( [mobileApi2TagCategoriesMenuitem] => 329 ) [mobileApi2TagCategories3] => stdClass Object ( [mobileApi2TagCategoriesMenuitem] => 327 ) [mobileApi2TagCategories4] => stdClass Object ( [mobileApi2TagCategoriesMenuitem] => 478 ) [mobileApi2TagCategories5] => stdClass Object ( [mobileApi2TagCategoriesMenuitem] => 494 ) ) [mobileApi2TagsSearchLimit] => 200 [mainFeedCategories] => Array ( [0] => 240 ) [feedLimit] => 50 [mostPopularFeedLimit] => 20 [feedItemImage] => 0 [feedImgSize] => S [feedItemIntroText] => 0 [feedTextWordLimit] => [feedItemFullText] => 1 [feedTextCharacterLimit] => 300 [feedItemSubtitle] => 1 [feedItemAuthor] => 0 [feedTtl] => 60 [feedDescription] => RSS feeds for Slobodna Dalmacija [feedItemTags] => 0 [feedItemVideo] => 0 [feedItemGallery] => 0 [feedItemAttachments] => 0 [feedBogusEmail] => [feedTopModules] => Array ( [0] => 105 ) [feedTopFbExcludeCategories] => Array ( [0] => 243 [1] => 353 [2] => 333 ) [introTextCleanup] => 0 [introTextCleanupExcludeTags] => [introTextCleanupTagAttr] => [fullTextCleanup] => 0 [fullTextCleanupExcludeTags] => [fullTextCleanupTagAttr] => [xssFiltering] => 0 [linkPopupWidth] => 900 [linkPopupHeight] => 600 [imagesQuality] => 100 [itemImageXS] => 100 [itemImageS] => 200 [itemImageM] => 400 [itemImageL] => 600 [itemImageXL] => 900 [itemImageGeneric] => 300 [catImageWidth] => 100 [catImageDefault] => 1 [userImageWidth] => 100 [userImageDefault] => 1 [commenterImgWidth] => 48 [onlineImageEditor] => sumopaint [imageTimestamp] => 0 [imageMemoryLimit] => [socialButtonCode] => [twitterUsername] => [facebookMetatags] => 1 [facebookImage] => Medium [comments] => 1 [commentsOrdering] => DESC [commentsLimit] => 10 [commentsFormPosition] => below [commentsPublishing] => 0 [commentsReporting] => 2 [commentsReportRecipient] => [inlineCommentsModeration] => 0 [gravatar] => 1 [antispam] => 0 [recaptchaForRegistered] => 1 [akismetForRegistered] => 1 [commentsFormNotes] => 1 [commentsFormNotesText] => [frontendEditing] => 1 [showImageTab] => 1 [showImageGalleryTab] => 1 [showVideoTab] => 1 [showExtraFieldsTab] => 1 [showAttachmentsTab] => 1 [showOCMPlugins] => 1 [sideBarDisplayFrontend] => 0 [staticURL] => https://static.slobodnadalmacija.hr [siteURL] => https://slobodnadalmacija.hr [sseHost] => sse.slobodnadalmacija.hr [lockingArticlesCategories] => Array ( [0] => 119 [1] => 424 [2] => 250 [3] => 251 [4] => 452 [5] => 252 [6] => 477 [7] => 253 [8] => 254 [9] => 255 [10] => 483 [11] => 256 [12] => 257 [13] => 258 [14] => 260 ) [lockingArticlesUnit] => YEAR [lockingArticlesQuantity] => 1 [photoGalleryExtraField] => 63 [photoGalleryExtraFieldON] => 2 [videoGalleryExtraField] => 67 [videoGalleryExtraFieldON] => 2 [tickerModules] => Array ( [0] => 408 [1] => 409 ) [gaEmail] => [mergeEditors] => 1 [sideBarDisplay] => 1 [attachmentsFolder] => [hideImportButton] => 0 [googleSearch] => 0 [googleSearchContainer] => ocmGoogleSearchContainer [OCMUserProfile] => 1 [OCMUserGroup] => 4 [redirect] => 101 [adminSearch] => simple [cookieDomain] => [gatherStatistics] => 1 [article_preview_ocm_category_id] => [taggingSystem] => 1 [lockTags] => 0 [showTagFilter] => 0 [ocmTagNorm] => 0 [ocmTagNormCase] => lower [ocmTagNormAdditionalReplacements] => [recaptcha_public_key] => marko_margeta [recaptcha_private_key] => zoey2013 [recaptcha_theme] => clean [recaptchaV2] => 1 [recaptchaOnRegistration] => 0 [akismetApiKey] => [stopForumSpam] => 0 [stopForumSpamApiKey] => [showItemsCounterAdmin] => 1 [showChildCatItems] => 1 [disableCompactOrdering] => 0 [metaDescLimit] => 150 [enforceSEFReplacements] => 0 [SEFReplacements] => À|A, Á|A, Â|A, Ã|A, Ä|A, Å|A, à|a, á|a, â|a, ã|a, ä|a, å|a, Ā|A, ā|a, Ă|A, ă|a, Ą|A, ą|a, Ç|C, ç|c, Ć|C, ć|c, Ĉ|C, ĉ|c, Ċ|C, ċ|c, Č|C, č|c, Ð|D, ð|d, Ď|D, ď|d, Đ|D, đ|d, È|E, É|E, Ê|E, Ë|E, è|e, é|e, ê|e, ë|e, Ē|E, ē|e, Ĕ|E, ĕ|e, Ė|E, ė|e, Ę|E, ę|e, Ě|E, ě|e, Ĝ|G, ĝ|g, Ğ|G, ğ|g, Ġ|G, ġ|g, Ģ|G, ģ|g, Ĥ|H, ĥ|h, Ħ|H, ħ|h, Ì|I, Í|I, Î|I, Ï|I, ì|i, í|i, î|i, ï|i, Ĩ|I, ĩ|i, Ī|I, ī|i, Ĭ|I, ĭ|i, Į|I, į|i, İ|I, ı|i, Ĵ|J, ĵ|j, Ķ|K, ķ|k, ĸ|k, Ĺ|L, ĺ|l, Ļ|L, ļ|l, Ľ|L, ľ|l, Ŀ|L, ŀ|l, Ł|L, ł|l, Ñ|N, ñ|n, Ń|N, ń|n, Ņ|N, ņ|n, Ň|N, ň|n, ʼn|n, Ŋ|N, ŋ|n, Ò|O, Ó|O, Ô|O, Õ|O, Ö|O, Ø|O, ò|o, ó|o, ô|o, õ|o, ö|o, ø|o, Ō|O, ō|o, Ŏ|O, ŏ|o, Ő|O, ő|o, Ŕ|R, ŕ|r, Ŗ|R, ŗ|r, Ř|R, ř|r, Ś|S, ś|s, Ŝ|S, ŝ|s, Ş|S, ş|s, Š|S, š|s, ſ|s, Ţ|T, ţ|t, Ť|T, ť|t, Ŧ|T, ŧ|t, Ù|U, Ú|U, Û|U, Ü|U, ù|u, ú|u, û|u, ü|u, Ũ|U, ũ|u, Ū|U, ū|u, Ŭ|U, ŭ|u, Ů|U, ů|u, Ű|U, ű|u, Ų|U, ų|u, Ŵ|W, ŵ|w, Ý|Y, ý|y, ÿ|y, Ŷ|Y, ŷ|y, Ÿ|Y, Ź|Z, ź|z, Ż|Z, ż|z, Ž|Z, ž|z, α|a, β|b, γ|g, δ|d, ε|e, ζ|z, η|h, θ|th, ι|i, κ|k, λ|l, μ|m, ν|n, ξ|x, ο|o, π|p, ρ|r, σ|s, τ|t, υ|y, φ|f, χ|ch, ψ|ps, ω|w, Α|A, Β|B, Γ|G, Δ|D, Ε|E, Ζ|Z, Η|H, Θ|Th, Ι|I, Κ|K, Λ|L, Μ|M, Ξ|X, Ο|O, Π|P, Ρ|R, Σ|S, Τ|T, Υ|Y, Φ|F, Χ|Ch, Ψ|Ps, Ω|W, ά|a, έ|e, ή|h, ί|i, ό|o, ύ|y, ώ|w, Ά|A, Έ|E, Ή|H, Ί|I, Ό|O, Ύ|Y, Ώ|W, ϊ|i, ΐ|i, ϋ|y, ς|s, А|A, Ӑ|A, Ӓ|A, Ә|E, Ӛ|E, Ӕ|E, Б|B, В|V, Г|G, Ґ|G, Ѓ|G, Ғ|G, Ӷ|G, y|Y, Д|D, Е|E, Ѐ|E, Ё|YO, Ӗ|E, Ҽ|E, Ҿ|E, Є|YE, Ж|ZH, Ӂ|DZH, Җ|ZH, Ӝ|DZH, З|Z, Ҙ|Z, Ӟ|DZ, Ӡ|DZ, Ѕ|DZ, И|I, Ѝ|I, Ӥ|I, Ӣ|I, І|I, Ї|JI, Ӏ|I, Й|Y, Ҋ|Y, Ј|J, К|K, Қ|Q, Ҟ|Q, Ҡ|K, Ӄ|Q, Ҝ|K, Л|L, Ӆ|L, Љ|L, М|M, Ӎ|M, Н|N, Ӊ|N, Ң|N, Ӈ|N, Ҥ|N, Њ|N, О|O, Ӧ|O, Ө|O, Ӫ|O, Ҩ|O, П|P, Ҧ|PF, Р|P, Ҏ|P, С|S, Ҫ|S, Т|T, Ҭ|TH, Ћ|T, Ќ|K, У|U, Ў|U, Ӳ|U, Ӱ|U, Ӯ|U, Ү|U, Ұ|U, Ф|F, Х|H, Ҳ|H, Һ|H, Ц|TS, Ҵ|TS, Ч|CH, Ӵ|CH, Ҷ|CH, Ӌ|CH, Ҹ|CH, Џ|DZ, Ш|SH, Щ|SHT, Ъ|A, Ы|Y, Ӹ|Y, Ь|Y, Ҍ|Y, Э|E, Ӭ|E, Ю|YU, Я|YA, а|a, ӑ|a, ӓ|a, ә|e, ӛ|e, ӕ|e, б|b, в|v, г|g, ґ|g, ѓ|g, ғ|g, ӷ|g, y|y, д|d, е|e, ѐ|e, ё|yo, ӗ|e, ҽ|e, ҿ|e, є|ye, ж|zh, ӂ|dzh, җ|zh, ӝ|dzh, з|z, ҙ|z, ӟ|dz, ӡ|dz, ѕ|dz, и|i, ѝ|i, ӥ|i, ӣ|i, і|i, ї|ji, Ӏ|i, й|y, ҋ|y, ј|j, к|k, қ|q, ҟ|q, ҡ|k, ӄ|q, ҝ|k, л|l, ӆ|l, љ|l, м|m, ӎ|m, н|n, ӊ|n, ң|n, ӈ|n, ҥ|n, њ|n, о|o, ӧ|o, ө|o, ӫ|o, ҩ|o, п|p, ҧ|pf, р|p, ҏ|p, с|s, ҫ|s, т|t, ҭ|th, ћ|t, ќ|k, у|u, ў|u, ӳ|u, ӱ|u, ӯ|u, ү|u, ұ|u, ф|f, х|h, ҳ|h, һ|h, ц|ts, ҵ|ts, ч|ch, ӵ|ch, ҷ|ch, ӌ|ch, ҹ|ch, џ|dz, ш|sh, щ|sht, ъ|a, ы|y, ӹ|y, ь|y, ҍ|y, э|e, ӭ|e, ю|yu, я|ya [ocmSef] => 0 [ocmSefLabelCat] => content [ocmSefLabelTag] => tag [ocmSefLabelUser] => author [ocmSefLabelSearch] => search [ocmSefLabelDate] => date [ocmSefLabelItem] => 0 [ocmSefLabelItemCustomPrefix] => [ocmSefInsertItemId] => 1 [ocmSefItemIdTitleAliasSep] => dash [ocmSefUseItemTitleAlias] => 1 [ocmSefInsertCatId] => 1 [ocmSefCatIdTitleAliasSep] => dash [ocmSefUseCatTitleAlias] => 1 [show_page_heading] => 0 [categories] => Array ( [0] => 241 ) [exclude_from_group_by_subcategories] => 0 [menu-anchor_css] => nav__link [menu_text] => 1 [menu_show] => 1 [menu-meta_description] => Najnovije vijesti iz Europe i svijeta. [menu-meta_keywords] => vijesti, zanimljivosti, politika, europa, svijet [secure] => 0 [page_title] => Svijet [page_description] => SiteMeta Description [page_rights] => [robots] => [inheritFrom] => 0 [num_leading_items] => 2 [num_leading_columns] => 1 [leadingImgSize] => Large [num_primary_items] => 4 [num_primary_columns] => 2 [primaryImgSize] => Medium [num_secondary_items] => 4 [num_secondary_columns] => 1 [secondaryImgSize] => Small [num_links] => 4 [num_links_columns] => 1 [linksImgSize] => XSmall [catCatalogMode] => 0 [catFeaturedItems] => 1 [catOrdering] => publishUp [catPagination] => 2 [catPaginationResults] => 1 [catTitle] => 1 [catTitleItemCounter] => 1 [catDescription] => 1 [catImage] => 1 [catFeedLink] => 0 [catFeedIcon] => 0 [subCategories] => 1 [subCatColumns] => 2 [subCatTitle] => 1 [subCatTitleItemCounter] => 1 [subCatDescription] => 1 [subCatImage] => 1 [catItemTitle] => 1 [catItemTitleLinked] => 1 [catItemFeaturedNotice] => 0 [catItemAuthor] => 1 [catItemDateCreated] => 1 [catItemRating] => 0 [catItemImage] => 1 [catItemIntroText] => 1 [catItemExtraFields] => 0 [catItemHits] => 0 [catItemCategory] => 1 [catItemTags] => 1 [catItemAttachments] => 0 [catItemAttachmentsCounter] => 0 [catItemVideo] => 0 [catItemVideoAutoPlay] => 0 [catItemImageGallery] => 0 [catItemDateModified] => 0 [catItemReadMore] => 1 [catItemCommentsAnchor] => 1 [catItemOCMPlugins] => 1 [itemDateCreated] => 1 [itemTitle] => 1 [itemFeaturedNotice] => 1 [itemAuthor] => 1 [itemFontResizer] => 0 [itemPrintButton] => 0 [itemEmailButton] => 1 [itemSocialButton] => 1 [itemVideoAnchor] => 1 [itemImageGalleryAnchor] => 1 [itemCommentsAnchor] => 1 [itemRating] => 0 [itemImage] => 1 [itemImgSize] => Large [itemImageMainCaption] => 1 [itemImageMainCredits] => 1 [itemIntroText] => 0 [itemFullText] => 1 [itemExtraFields] => 1 [itemDateModified] => 1 [itemHits] => 0 [itemCategory] => 0 [itemTags] => 1 [itemAttachments] => 1 [itemAttachmentsCounter] => 1 [itemVideo] => 1 [itemVideoAutoPlay] => 0 [itemVideoCaption] => 1 [itemVideoCredits] => 1 [itemImageGallery] => 0 [itemNavigation] => 0 [itemComments] => 1 [itemTwitterButton] => 1 [itemFacebookButton] => 1 [itemGooglePlusOneButton] => 1 [itemAuthorBlock] => 0 [itemAuthorImage] => 0 [itemAuthorDescription] => 0 [itemAuthorURL] => 1 [itemAuthorEmail] => 0 [itemAuthorLatest] => 0 [itemAuthorLatestLimit] => 5 [itemRelated] => 1 [itemRelatedLimit] => 2 [itemRelatedTitle] => 1 [itemRelatedCategory] => 1 [itemRelatedImageSize] => Medium [itemRelatedIntrotext] => 0 [itemRelatedFulltext] => 0 [itemRelatedAuthor] => 0 [itemRelatedMedia] => 1 [itemRelatedImageGallery] => 1 [itemOCMPlugins] => 1 [recaptcha] => ) [initialized:protected] => 1 [separator] => . ) [metadesc] => [metadata] => robots= author= [metakey] => [plugins] => {"incptvocmimagegalleryIGParameters":"default","incptvocmimagegalleryocmIGposition":"OcmAfterDisplayContent","incptvocmimagegalleryocmIGtheme":"CameraSlideshow","incptvocmimagegalleryImages":["\/images\/slike\/2021\/10\/01\/19520624.jpg","\/images\/slike\/2021\/10\/01\/19105182.jpg"],"incptvocmimagegalleryImageTitles":["AFP","Julian Stratenschulte\/AFP"],"incptvocmimagegalleryImageDescriptions":["Tablete Molnupiravir","Luka \u010ci\u010din-\u0160ain"],"incptvocmimagegalleryImageFocus":["50:50","50:50"],"incptvocmimagegalleryImageDimensions":[{"size0":"1024x575","hd_19520624_1920.jpg":"1920x1080","k_19520624_1280.jpg":"1280x1280","k_19520624_1024.jpg":"1024x1024","k_19520624_640.jpg":"640x640","k_19520624_480.jpg":"480x480","k_19520624_340.jpg":"340x340","k_19520624_220.jpg":"220x220","o_19520624_1280.jpg":"1280x718","o_19520624_1024.jpg":"1024x575","o_19520624_640.jpg":"640x359","o_19520624_480.jpg":"480x269","o_19520624_340.jpg":"340x190","o_19520624_220.jpg":"220x123","h_19520624_1280.jpg":"1280x854","h_19520624_1024.jpg":"1024x683","h_19520624_640.jpg":"640x427","h_19520624_480.jpg":"480x320","h_19520624_340.jpg":"340x227","h_19520624_220.jpg":"220x147","pp_19520624_1280.jpg":"1006x1280","pp_19520624_1024.jpg":"805x1024","pp_19520624_640.jpg":"503x640","pp_19520624_480.jpg":"377x480","pp_19520624_340.jpg":"267x340","pp_19520624_220.jpg":"173x220"},{"size0":"1024x668","hd_19105182_1920.jpg":"1920x1080","k_19105182_1280.jpg":"1280x1280","k_19105182_1024.jpg":"1024x1024","k_19105182_640.jpg":"640x640","k_19105182_480.jpg":"480x480","k_19105182_340.jpg":"340x340","k_19105182_220.jpg":"220x220","o_19105182_1280.jpg":"1280x835","o_19105182_1024.jpg":"1024x668","o_19105182_640.jpg":"640x417","o_19105182_480.jpg":"480x313","o_19105182_340.jpg":"340x221","o_19105182_220.jpg":"220x143","h_19105182_1280.jpg":"1280x854","h_19105182_1024.jpg":"1024x683","h_19105182_640.jpg":"640x427","h_19105182_480.jpg":"480x320","h_19105182_340.jpg":"340x227","h_19105182_220.jpg":"220x147","pp_19105182_1280.jpg":"1006x1280","pp_19105182_1024.jpg":"805x1024","pp_19105182_640.jpg":"503x640","pp_19105182_480.jpg":"377x480","pp_19105182_340.jpg":"267x340","pp_19105182_220.jpg":"173x220"}]} [language] => * [multi_author] => 0 [type_id] => 100 [category] => TableOCMCategory Object ( [id] => 241 [name] => Svijet [alias] => svijet [description] => [parent] => 119 [extraFieldsGroup] => 9 [published] => 1 [image] => [access] => 1 [ordering] => 2 [params] => {"inheritFrom":"119","catMetaDesc":"","catMetaKey":"","catMetaRobots":"","catMetaAuthor":"","theme":"","num_leading_items":"2","num_leading_columns":"1","leadingImgSize":"Large","num_primary_items":"4","num_primary_columns":"2","primaryImgSize":"Medium","num_secondary_items":"4","num_secondary_columns":"1","secondaryImgSize":"Small","num_links":"4","num_links_columns":"1","linksImgSize":"XSmall","catCatalogMode":"0","catFeaturedItems":"1","catOrdering":"publishUp","catPagination":"2","catPaginationResults":"1","catTitle":"1","catTitleItemCounter":"1","catDescription":"1","catImage":"1","catFeedLink":"0","catFeedIcon":"0","subCategories":"1","subCatColumns":"2","subCatOrdering":"","subCatTitle":"1","subCatTitleItemCounter":"1","subCatDescription":"1","subCatImage":"1","itemImageXS":"","itemImageS":"","itemImageM":"","itemImageL":"","itemImageXL":"","catItemTitle":"1","catItemTitleLinked":"1","catItemFeaturedNotice":"0","catItemAuthor":"1","catItemDateCreated":"1","catItemRating":"0","catItemImage":"1","catItemIntroText":"1","catItemIntroTextWordLimit":"","catItemExtraFields":"0","catItemHits":"0","catItemCategory":"1","catItemTags":"1","catItemAttachments":"0","catItemAttachmentsCounter":"0","catItemVideo":"0","catItemVideoWidth":"","catItemVideoHeight":"","catItemAudioWidth":"","catItemAudioHeight":"","catItemVideoAutoPlay":"0","catItemImageGallery":"0","catItemImageGalleryWidth":"","catItemImageGalleryHeight":"","catItemDateModified":"0","catItemReadMore":"1","catItemCommentsAnchor":"1","catItemOCMPlugins":"1","itemDateCreated":"1","itemTitle":"1","itemFeaturedNotice":"1","itemAuthor":"1","itemFontResizer":"1","itemPrintButton":"0","itemEmailButton":"1","itemSocialButton":"1","itemVideoAnchor":"1","itemImageGalleryAnchor":"1","itemCommentsAnchor":"1","itemRating":"0","itemImage":"1","itemImgSize":"Large","itemImageMainCaption":"1","itemImageMainCredits":"1","itemIntroText":"0","itemFullText":"1","itemExtraFields":"0","itemDateModified":"1","itemHits":"0","itemCategory":"0","itemTags":"1","itemAttachments":"1","itemAttachmentsCounter":"1","itemVideo":"1","itemVideoWidth":"","itemVideoHeight":"","itemAudioWidth":"","itemAudioHeight":"","itemVideoAutoPlay":"0","itemVideoCaption":"1","itemVideoCredits":"1","itemImageGallery":"0","itemImageGalleryWidth":"","itemImageGalleryHeight":"","itemNavigation":"0","itemComments":"1","itemTwitterButton":"1","itemFacebookButton":"1","itemGooglePlusOneButton":"1","itemAuthorBlock":"0","itemAuthorImage":"0","itemAuthorDescription":"0","itemAuthorURL":"0","itemAuthorEmail":"0","itemAuthorLatest":"0","itemAuthorLatestLimit":"5","itemRelated":"0","itemRelatedLimit":"5","itemRelatedTitle":"1","itemRelatedCategory":"0","itemRelatedImageSize":"0","itemRelatedIntrotext":"1","itemRelatedFulltext":"0","itemRelatedAuthor":"0","itemRelatedMedia":"0","itemRelatedImageGallery":"0","itemOCMPlugins":"1"} [trash] => 0 [plugins] => {"customparams_created":"2019-11-04 19:44:34","customparams_modified":"2019-11-04 19:44:34","customparams_videobg":"","customparams_countdown_module":"","customparams_search_template":""} [language] => * [container] => 0 [container_name] => [_tbl:protected] => #__ocm_categories [_tbl_key:protected] => id [_tbl_keys:protected] => Array ( [0] => id ) [_db:protected] => JDatabaseDriverMysqli_Exabyte Object ( [name] => mysqli [serverType] => mysql [connection:protected] => mysqli Object ( [affected_rows] => 1 [client_info] => mysqlnd 5.0.12-dev - 20150407 - $Id: 7cc7cc96e675f6d72e5cf0f267f48e167c2abb23 $ [client_version] => 50012 [connect_errno] => 0 [connect_error] => [errno] => 0 [error] => [error_list] => Array ( ) [field_count] => 18 [host_info] => 127.0.0.1 via TCP/IP [info] => [insert_id] => 0 [server_info] => 5.5.30 [server_version] => 50530 [stat] => Uptime: 7749996 Threads: 4 Questions: 1563873409 Slow queries: 4770319 [sqlstate] => 00000 [protocol_version] => 10 [thread_id] => 111582238 [warning_count] => 0 ) [nameQuote:protected] => ` [nullDate:protected] => 0000-00-00 00:00:00 [_database:JDatabaseDriver:private] => sdproductiondb [count:protected] => 52 [cursor:protected] => [debug:protected] => [limit:protected] => 0 [log:protected] => Array ( ) [timings:protected] => Array ( ) [callStacks:protected] => Array ( ) [offset:protected] => 0 [options:protected] => Array ( [driver] => mysqli_exabyte [host] => 127.0.0.1 [user] => proxy_user_front03 [password] => b3hX5DrKwjx6 [database] => sdproductiondb [prefix] => sk_ [select] => 1 [port] => 6033 [socket] => ) [sql:protected] => JDatabaseQueryMysqli Object ( [offset:protected] => 0 [limit:protected] => 0 [db:protected] => JDatabaseDriverMysqli_Exabyte Object *RECURSION* [sql:protected] => [type:protected] => select [element:protected] => [select:protected] => JDatabaseQueryElement Object ( [name:protected] => SELECT [elements:protected] => Array ( [0] => category.* [1] => IF(ISNULL(container.catid),false,true) AS container [2] => container.name AS container_name [3] => SEFURL_cr.menuItemID AS sefurl_belonging_menu_item ) [glue:protected] => , ) [delete:protected] => [update:protected] => [insert:protected] => [from:protected] => JDatabaseQueryElement Object ( [name:protected] => FROM [elements:protected] => Array ( [0] => `#__ocm_categories` AS `category` ) [glue:protected] => , ) [join:protected] => Array ( [0] => JDatabaseQueryElement Object ( [name:protected] => LEFT JOIN [elements:protected] => Array ( [0] => #__ocm_containers AS container ON category.id = container.catid ) [glue:protected] => , ) [1] => JDatabaseQueryElement Object ( [name:protected] => LEFT JOIN [elements:protected] => Array ( [0] => #__ocm_sefurl_category_menu_relation AS SEFURL_cr ON category.id = SEFURL_cr.categoryID ) [glue:protected] => , ) ) [set:protected] => [where:protected] => JDatabaseQueryElement Object ( [name:protected] => WHERE [elements:protected] => Array ( [0] => `category`.`id` = '240' ) [glue:protected] => AND ) [group:protected] => [having:protected] => [columns:protected] => [values:protected] => [order:protected] => [autoIncrementField:protected] => [call:protected] => [exec:protected] => [union:protected] => [unionAll:protected] => [selectRowNumber:protected] => ) [tablePrefix:protected] => sk_ [utf:protected] => 1 [utf8mb4:protected] => 1 [errorNum:protected] => 0 [errorMsg:protected] => [transactionDepth:protected] => 0 [disconnectHandlers:protected] => Array ( ) [ocmConfig] => Array ( ) ) [_trackAssets:protected] => [_rules:protected] => [_locked:protected] => [_autoincrement:protected] => 1 [_observers:protected] => JObserverUpdater Object ( [aliases:protected] => Array ( ) [observers:protected] => Array ( ) [doCallObservers:protected] => 1 ) [_columnAlias:protected] => Array ( ) [_jsonEncode:protected] => Array ( ) [_errors:protected] => Array ( ) [year_lookup] => 0 [link] => /vijesti/svijet ) [additional_categories] => Array ( [0] => stdClass Object ( [id] => 241 [name] => Svijet [alias] => svijet [parent] => 119 [published] => 1 [trash] => 0 [link] => /vijesti/svijet ) ) [link] => /vijesti/svijet/jesmo-li-dosli-do-prekretnice-u-borbi-protiv-covida-prvi-rezultati-testiranja-merckova-lijeka-obecavaju-evo-o-kakvim-se-tabletama-radi-1131624 [printLink] => /vijesti/svijet/jesmo-li-dosli-do-prekretnice-u-borbi-protiv-covida-prvi-rezultati-testiranja-merckova-lijeka-obecavaju-evo-o-kakvim-se-tabletama-radi-1131624?tmpl=component&print=1 [tags] => Array ( [0] => stdClass Object ( [id] => 651401 [name] => molnupiravir [published] => 1 [section] => [subsection] => [weight] => [created] => 2021-10-01 17:08:53 [main_article_id] => 0 [alias] => molnupiravir [link] => /tag/molnupiravir ) [1] => stdClass Object ( [id] => 632622 [name] => Merck [published] => 1 [section] => [subsection] => [weight] => [created] => 2021-03-06 22:47:34 [main_article_id] => 0 [alias] => merck [link] => /tag/merck ) [2] => stdClass Object ( [id] => 619693 [name] => lijek protiv koronavirusa [published] => 1 [section] => [subsection] => [weight] => [created] => 2020-10-06 14:33:00 [main_article_id] => 0 [alias] => lijek-protiv-koronavirusa [link] => /tag/lijek-protiv-koronavirusa ) [3] => stdClass Object ( [id] => 636324 [name] => Luka Čičin Šain [published] => 1 [section] => [subsection] => [weight] => [created] => 2021-04-17 21:20:33 [main_article_id] => 0 [alias] => luka-cicin-sain [link] => /tag/luka-cicin-sain ) ) [imageXSmall] => [imageSmall] => [imageMedium] => [imageLarge] => [imageXLarge] => [extraFields] => stdClass Object ( [SuperscriptTitle] => stdClass Object ( [id] => 2 [name] => Superscript Title [value] => prošao prvu fazu [type] => textarea [group] => 9 [published] => 1 [ordering] => 2 [alias] => SuperscriptTitle ) [contains_infographic] => stdClass Object ( [id] => 61 [name] => Contains Infographic [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 4 [alias] => contains_infographic ) [Withoutads] => stdClass Object ( [id] => 62 [name] => Without ads [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 5 [alias] => Withoutads ) [Photo_gallery] => stdClass Object ( [id] => 63 [name] => Photo gallery [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 6 [alias] => Photo_gallery ) [promo] => stdClass Object ( [id] => 64 [name] => Promo [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 7 [alias] => promo ) [contains_video] => stdClass Object ( [id] => 67 [name] => Contains video [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 9 [alias] => contains_video ) [premium_content] => stdClass Object ( [id] => 68 [name] => Premium content [value] => ON [type] => radio [group] => 9 [published] => 1 [ordering] => 10 [alias] => premium_content ) [exclude_comments] => stdClass Object ( [id] => 69 [name] => Exclude comments [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 11 [alias] => exclude_comments ) [open_link_in_new_window] => stdClass Object ( [id] => 70 [name] => Open link in new window [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 12 [alias] => open_link_in_new_window ) [horizontal_crop_of_the_main_photo] => stdClass Object ( [id] => 71 [name] => Horizontal crop of the main photo [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 13 [alias] => horizontal_crop_of_the_main_photo ) [no_index] => stdClass Object ( [id] => 73 [name] => No-index [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 15 [alias] => no_index ) [no_cache] => stdClass Object ( [id] => 74 [name] => No-cache [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 16 [alias] => no_cache ) [dont_show_on_the_front_page] => stdClass Object ( [id] => 77 [name] => Don't show on the front page [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 17 [alias] => dont_show_on_the_front_page ) [related_on_bottom] => stdClass Object ( [id] => 78 [name] => Related on bottom [value] => ON [type] => radio [group] => 9 [published] => 1 [ordering] => 18 [alias] => related_on_bottom ) [live_button] => stdClass Object ( [id] => 79 [name] => Live button [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 19 [alias] => live_button ) [instant_articles] => stdClass Object ( [id] => 87 [name] => Instant articles [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 28 [alias] => instant_articles ) [s_preporucuje] => stdClass Object ( [id] => 91 [name] => S preporučuje [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 29 [alias] => s_preporucuje ) [s_voli] => stdClass Object ( [id] => 92 [name] => S voli [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 30 [alias] => s_voli ) [layout_with_three_photos] => stdClass Object ( [id] => 93 [name] => Layout with three photos [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 31 [alias] => layout_with_three_photos ) [gallery_in_the_article] => stdClass Object ( [id] => 94 [name] => Gallery in the article [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 32 [alias] => gallery_in_the_article ) [required_views] => stdClass Object ( [id] => 95 [name] => Required views [value] => 0 [type] => textfield [group] => 9 [published] => 1 [ordering] => 33 [alias] => required_views ) [fullhd_image] => stdClass Object ( [id] => 96 [name] => FullHD image [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 34 [alias] => fullhd_image ) [paid_article] => stdClass Object ( [id] => 98 [name] => Paid Article [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 36 [alias] => paid_article ) ) [attachments] => Array ( ) [cleanTitle] => Jesmo li došli do prekretnice u borbi protiv covida? Prvi rezultati testiranja Merckova lijeka obećavaju, evo o kakvim se tabletama radi [num_of_authors] => 0 [author] => Joomla\CMS\User\User Object ( [isRoot:protected] => [id] => [name] => [username] => [email] => [password] => [password_clear] => [block] => [sendEmail] => [registerDate] => [lastvisitDate] => [activation] => [params] => [groups] => Array ( ) [guest] => 1 [lastResetTime] => [resetCount] => [requireReset] => [_params:protected] => Joomla\Registry\Registry Object ( [data:protected] => stdClass Object ( ) [initialized:protected] => [separator] => . ) [_authGroups:protected] => [_authLevels:protected] => [_authActions:protected] => [_errorMsg:protected] => [userHelper:protected] => Joomla\CMS\User\UserWrapper Object ( ) [_errors:protected] => Array ( ) [link] => /autor/2024-05-16-00-02-11-264 [profile] => stdClass Object ( [id] => 1342 [gender] => m [description] => [image] => 1342.png [url] => [group] => 0 [plugins] => {"customparams_author_school":"","customparams_author_title":"","customparams_author_title_categoryid":"3","customparams_fb_link":"","customparams_tw_link":""} ) [avatar] => /components/com_ocm/images/placeholder/user.png ) [numOfComments] => 0 [mainImage] => https://static.slobodnadalmacija.hr/images/slike/2021/10/01/19520624.jpg [galleryCount] => 2 [hasImage] => 1 [mainImageAuthor] => AFP [mainImageDesc] => Tablete Molnupiravir [popup_gallery] => Array ( [0] => stdClass Object ( [src] => https://static.slobodnadalmacija.hr/images/slike/2021/10/01/19520624.jpg [title] => AFPTablete Molnupiravir ) [1] => stdClass Object ( [src] => https://static.slobodnadalmacija.hr/images/slike/2021/10/01/19105182.jpg [title] => Julian Stratenschulte/AFPLuka Čičin-Šain ) ) [bgPosition] => [videoType] => allvideos [text] => {OCMSplitter}

Dok su u početku pandemije farmaceutske kompanije uglavnom bile fokusirane na razvoj cjepiva, sada mnoge od njih pokušavaju razviti specifične lijekove protiv covida-19. Tako je multinacionalni farmaceutski div Merck & Co. u suradnji s biotehnološkom kompanijom Ridgeback Biotherapeutics razvio antivirusni lijek molnupiravir koji je već prošao prvu fazu kliničkih ispitivanja, piše Jutarnji list.

- Riječ je o lijeku koji je po svom djelovanju sličan remdesiviru koji se već koristi u liječenju covida-19, i koji blokira replikaciju virusnog genoma. Molnupiravir je, također, analog nukleotida, a virusnu replikaciju ometa tako da se ubacuje u lanac virusne mRNA kad se virus razmnaža čime nastaju nepotpuni lanci koji se ne mogu dalje razmnažati. Međutim, remdesivir se mora davati intravenski i stoga nije praktično davati ga osobama koje ne leže u bolnici. Stoga se remdesivir koristi kad je bolest već uznapredovala i tada nije naročito efikasan – pojasnio je virusni imunolog dr. Luka Čičin-Šain, voditelj Odjela za virusnu imunologiju u Helmholtz centru za infektivna istraživanja u Braunschweigu.

- Za razliku od remdesivira, molnupiravir se prima kao tableta i može ga se početi davati i u ranijim fazama bolesti, što je korisno jer se time sprječava da se virus proširi po plućima, što budi nadu da bi njegov učinak mogao biti bolji. Molnupiravir se nalazi u kombiniranoj drugoj i trećoj fazi kliničkog istraživanja što znači da još nije odobren za upotrebu – dodao je Čičin-Šain.

Molnupiravir je antivirusni lijek širokog spektra što znači da može djelovati protiv velikog broja virusa. Njegov razvoj započeo je još 2013. godine na američkom Sveučilištu Emory, odnosno sveučilišnoj spin-off kompaniji Drug Innovation Ventures at Emory (DRIVE) koju je zatim kupio Ridgeback Biotherapeutics iz Miamija. Prvobitna ideja je bila testirati molnupiravir u kliničkim pokusima kao potencijalni lijek protiv gripe, no kada je buknula pandemija koronavirusa, plan je izmijenjen. Kako se prošlog proljeća molnupiravir pokazao učinkovit u liječenju laboratorijskih miševa zaraženih koronavirusom, kompanija Ridgeback Biotherapeutics se, u suradnji s farmaceutskim divom Merck&Co., preusmjerila na razvoj lijeka protiv covida-19.

---

image
Luka Čičin-Šain
Julian Stratenschulte/AFP
---

Izvršni direktor Mercka Robert Davis nedavno je izjavio da se idućih tjedana očekuju preliminarni rezultati druge i treće faze kliničkih ispitivanja u koju je uključeno 1850 ispitanika. Budu li ti klinički pokusi uspješni, kompanija bi već krajem godine od američke Agencije za hranu i lijekove (FDA) zatražila dozvolu za hitnu uporabu. Lijek bi se uzimao pet do 10 dana nakon pojave simptoma covida-19 i to dva puta dnevno.

Uz molnupiravir, obećavajuće rezultate u kliničkim pokusima pokazuju još dva antivirusna lijeka: Pfizerov PF-07321332 i AT-527, koji su razvili Roche i Atea Pharmaceuticals. Oba lijeka, koji su također tablete, djeluju tako da blokiraju enzime SARS-Cov-2 neophodne za umnažanje virusa i širenje zaraze. Pfizer je 1. rujna pokrenuo kombinirano ispitivanje faze 2 i 3 svog lijeka, a dužnosnici kompanije Atea Pharmaceuticals rekli su da očekuju rezultate ispitivanja u fazi 2 i fazi 3 krajem ove godine.

- Oralni antivirusni lijekovi imaju potencijal ne samo skratiti trajanje covida-19, već imaju i potencijal ograničiti prijenos na ljude u vašem kućanstvu ako ste bolesni - rekao je za CNN Timothy Sheahan, virolog sa Sveučilišta Sjeverna Karolina.

Luka Čičin-Šain upozorava kako je glavni problem kod akutnih respiratornih infekcija, bilo da je riječ o covidu ili gripi, da se zaraza kod pacijenta razvija jako brzo.

- Mislim da razmišljanja idu u smjeru individulazirane terapije kako bi se lijekovi profilaktički davali starijima od 70 godina, pretilima, osobama koje pate od dijabetesa i kardiovaskularnih bolesti itd. čim im se dijagnosticira covid, a ne kada su već u jedinici intenzivnog liječenja. No, takvi lijekovi trebaju biti jednostavni u primjeni van bolnica ili ordinacija. Idealan bi bio lijek koga se može koristiti kao tabletu, slično antibioticima. Ova studija budi nadu da bi takav lijek, koji bi bio učinkovit kod koronavirusa, uskoro mogao dokazati svoju efikasnost i u kliničkim uvjetima – rekao je Čičin-Šain.

[jcfields] => Array ( ) [event] => stdClass Object ( [BeforeDisplay] => [AfterDisplay] => [AfterDisplayTitle] => [BeforeDisplayContent] => [AfterDisplayContent] => [OCMBeforeDisplay] => [OCMAfterDisplay] => [OCMAfterDisplayTitle] => [OCMBeforeDisplayContent] => [OCMAfterDisplayContent] =>
AFP Julian Stratenschulte/AFP
AFP
Tablete Molnupiravir
Julian Stratenschulte/AFP
Luka Čičin-Šain
[OCMUserDisplay] => [OCMCommentsCounter] => [OCMCommentsBlock] => ) [image] => [imageWidth] => 600 [comments] => Array ( ) [absoluteURL] => https://slobodnadalmacija.hr/vijesti/svijet/jesmo-li-dosli-do-prekretnice-u-borbi-protiv-covida-prvi-rezultati-testiranja-merckova-lijeka-obecavaju-evo-o-kakvim-se-tabletama-radi-1131624 [emailLink] => /component/mailto/?tmpl=component&template=site&link=6b15d4bc49380acd0d45e7ecd1506fb9d3305278 [twitterURL] => http://twitter.com/intent/tweet?text=Jesmo+li+do%C5%A1li+do+prekretnice+u+borbi+protiv+covida%3F+Prvi+rezultati+testiranja+Merckova+lijeka+obe%C4%87avaju%2C+evo+o+kakvim+se+tabletama+radi&url=https%3A%2F%2Fslobodnadalmacija.hr%2Fvijesti%2Fsvijet%2Fjesmo-li-dosli-do-prekretnice-u-borbi-protiv-covida-prvi-rezultati-testiranja-merckova-lijeka-obecavaju-evo-o-kakvim-se-tabletama-radi-1131624 [socialLink] => https%3A%2F%2Fslobodnadalmacija.hr%2Fvijesti%2Fsvijet%2Fjesmo-li-dosli-do-prekretnice-u-borbi-protiv-covida-prvi-rezultati-testiranja-merckova-lijeka-obecavaju-evo-o-kakvim-se-tabletama-radi-1131624 )
Array ( [1] => stdClass Object ( [id] => 2 [name] => Superscript Title [value] => prošao prvu fazu [type] => textarea [group] => 9 [published] => 1 [ordering] => 2 [alias] => SuperscriptTitle ) [2] => stdClass Object ( [id] => 61 [name] => Contains Infographic [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 4 [alias] => contains_infographic ) [3] => stdClass Object ( [id] => 62 [name] => Without ads [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 5 [alias] => Withoutads ) [4] => stdClass Object ( [id] => 63 [name] => Photo gallery [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 6 [alias] => Photo_gallery ) [5] => stdClass Object ( [id] => 64 [name] => Promo [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 7 [alias] => promo ) [7] => stdClass Object ( [id] => 67 [name] => Contains video [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 9 [alias] => contains_video ) [8] => stdClass Object ( [id] => 68 [name] => Premium content [value] => ON [type] => radio [group] => 9 [published] => 1 [ordering] => 10 [alias] => premium_content ) [9] => stdClass Object ( [id] => 69 [name] => Exclude comments [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 11 [alias] => exclude_comments ) [10] => stdClass Object ( [id] => 70 [name] => Open link in new window [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 12 [alias] => open_link_in_new_window ) [11] => stdClass Object ( [id] => 71 [name] => Horizontal crop of the main photo [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 13 [alias] => horizontal_crop_of_the_main_photo ) [12] => stdClass Object ( [id] => 73 [name] => No-index [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 15 [alias] => no_index ) [13] => stdClass Object ( [id] => 74 [name] => No-cache [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 16 [alias] => no_cache ) [14] => stdClass Object ( [id] => 77 [name] => Don't show on the front page [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 17 [alias] => dont_show_on_the_front_page ) [15] => stdClass Object ( [id] => 78 [name] => Related on bottom [value] => ON [type] => radio [group] => 9 [published] => 1 [ordering] => 18 [alias] => related_on_bottom ) [16] => stdClass Object ( [id] => 79 [name] => Live button [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 19 [alias] => live_button ) [25] => stdClass Object ( [id] => 87 [name] => Instant articles [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 28 [alias] => instant_articles ) [26] => stdClass Object ( [id] => 91 [name] => S preporučuje [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 29 [alias] => s_preporucuje ) [27] => stdClass Object ( [id] => 92 [name] => S voli [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 30 [alias] => s_voli ) [28] => stdClass Object ( [id] => 93 [name] => Layout with three photos [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 31 [alias] => layout_with_three_photos ) [29] => stdClass Object ( [id] => 94 [name] => Gallery in the article [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 32 [alias] => gallery_in_the_article ) [30] => stdClass Object ( [id] => 95 [name] => Required views [value] => 0 [type] => textfield [group] => 9 [published] => 1 [ordering] => 33 [alias] => required_views ) [31] => stdClass Object ( [id] => 96 [name] => FullHD image [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 34 [alias] => fullhd_image ) [32] => stdClass Object ( [id] => 98 [name] => Paid Article [value] => OFF [type] => radio [group] => 9 [published] => 1 [ordering] => 36 [alias] => paid_article ) )
StoryEditorOCM
Svijetprošao prvu fazu

Jesmo li došli do prekretnice u borbi protiv covida? Prvi rezultati testiranja Merckova lijeka obećavaju, evo o kakvim se tabletama radi

Piše Tanja Rudež/JL
1. listopada 2021. - 17:07
Tablete Molnupiravir
PREMIUM
Tablete MolnupiravirAFP

Dok su u početku pandemije farmaceutske kompanije uglavnom bile fokusirane na razvoj cjepiva, sada mnoge od njih pokušavaju razviti specifične lijekove protiv covida-19. Tako je multinacionalni farmaceutski div Merck & Co. u suradnji s biotehnološkom kompanijom Ridgeback Biotherapeutics razvio antivirusni lijek molnupiravir koji je već prošao prvu fazu kliničkih ispitivanja, piše Jutarnji list.

- Riječ je o lijeku koji je po svom djelovanju sličan remdesiviru koji se već koristi u liječenju covida-19, i koji blokira replikaciju virusnog genoma. Molnupiravir je, također, analog nukleotida, a virusnu replikaciju ometa tako da se ubacuje u lanac virusne mRNA kad se virus razmnaža čime nastaju nepotpuni lanci koji se ne mogu dalje razmnažati. Međutim, remdesivir se mora...

#MOLNUPIRAVIR#MERCK#LIJEK PROTIV KORONAVIRUSA#LUKA ČIČIN ŠAIN
Želite li dopuniti temu ili prijaviti pogrešku u tekstu?
16. svibanj 2024 02:02